Toronto Stock Exchange Symbol: DND
MISSISSAUGA, ON, Jan. 21, 2014 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:
DND) ("Cipher" or "the Company") today announced that its marketing
partner for Absoricaä has reached a cumulative sales milestone in
accordance with the parties' commercial agreement, triggering a
one-time US$5.0 million (net) payment to Cipher. This revenue will be
included in Cipher's Q4 2013 financial results, which the Company plans
to report in late February.
About Cipher Pharmaceuticals Inc.
Cipher Pharmaceuticals (TSX: DND) is a growing specialty pharmaceutical
company with three commercial products and a fourth in development. Our
product candidates are typically improved formulations of successful,
currently marketed drugs. We in-license a product, manage the required
clinical development and regulatory approval process, and either
out-license it to a marketing partner, or, in Canada, we may market the
product ourselves. Our core capabilities are in clinical and regulatory
affairs, product licensing, supply chain management, and marketing and
sales. Since the Company was founded in 2000, we have achieved final
regulatory approval in the U.S. and Canada for all three of our
original products and completed six marketing partnerships, generating
growing licensing revenue.
SOURCE: Cipher Pharmaceuticals Inc.
For further information:
(416) 815-0700 ext 278
(416) 815-0080 fax
President and CEO
(905) 602-5840 ext 324
(905) 602-0628 fax